滤泡性淋巴瘤管理的未来:即将出现的策略
滤泡性淋巴瘤(FL)是最常见的惰性淋巴瘤亚型,近年治疗进展使中位总生存显著改善,多数患者最终死于其他原因。多种新型免疫治疗和靶向治疗已获批用于复发难治性疾病,但早期进展和转化为侵袭性淋巴瘤仍是需进一步创新的关键问题。本文展望双特异性抗体更早期使用及新组合、新一代双特异性抗体和嵌合抗原受体T细胞疗法以降低毒性提高疗效、循环肿瘤DNA检测指导治疗选择与疗程、生活质量工具辅助多选项患者决策,以及未来FL不再被称为「不可治愈」的愿景。
要点
- FL治疗进展使中位总生存显著改善,多数患者最终死于其他原因。
- 多种新型免疫治疗和靶向治疗已获批用于复发难治性FL。
- 早期进展和转化为侵袭性淋巴瘤仍是需进一步创新的关键问题。
核心结论
- FL治疗已取得显著进展,中位总生存显著改善,多数患者最终死于其他原因。
- 早期进展和转化为侵袭性淋巴瘤仍是需进一步创新的关键问题。
- 未来期望双特异性抗体更早期使用及新组合,新一代双特异性抗体和CAR-T疗法以降低毒性提高疗效。
- 循环肿瘤DNA检测可能实现更合理的治疗选择、疗程指导或治疗调整,并可能替代随访影像。
- 期望更广泛使用生活质量工具为长期预后良好且有多种选择的患者选择治疗。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- FL是最常见的惰性淋巴瘤亚型,近年治疗进展使中位总生存显著改善。
- 多数FL患者现在将死于其他原因。
- 多种新型免疫治疗和其他靶向治疗已获批用于复发和难治性疾病。
- 早期进展和转化为侵袭性淋巴瘤仍是需进一步创新的关键问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progress in the therapy of follicular lymphoma (FL), the most common indolent lymphoma subtype, has been achieved in recent years with significant improvement in median overall survival. Most patients diagnosed with FL will now die from other causes. Multiple novel immunotherapy and other targeted therapies are now approved for relapsed and refractory disease. However, early progression and transformation to aggressive lymphoma remain key issues requiring further innovation. We expect that bispecific antibodies will likely move to earlier use and in novel combinations. Future generations of these and chimeric antigen receptor T-cell therapy will be developed in an effort to minimize toxicity and improve efficacy. New technologies, such as circulating tumor DNA assays, may enable more rational selection and guidance of therapy duration or changes in treatment, as well as possibly substituting for follow-up imaging while monitoring patients. We also look forward to more extensive use of quality-of-life tools to select treatment for patients who have a favorable long-term outlook with multiple options. Finally, patients and clinicians now envision a day when FL is no longer referred to as "incurable." Having a definition and possibility of a "cure" and being able to optimize such a mindset in the approach of FL would represent a major advance in our future management strategy.
引用
- Mulvey E, Rutherford SC, Leonard JP, et al. The future of follicular lymphoma management: strategies on the horizon. Blood. 2025. PMID: 40019447. doi:10.1182/blood.2024026017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。